An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
Authors:
- Oskar WysockiOWOskar Wysocki
- Cong ZhouCZCong Zhou
- Jacobo RogadoJRJacobo Rogado
- Prerana HuddarPHPrerana Huddar
- Rohan ShottonRSRohan Shotton
- Ann TiveyATAnn Tivey
- Laurence AlbigesLALaurence Albiges
- Angelos AngelakasAAAngelos Angelakas
- Dirk ArnoldDADirk Arnold
- Theingi AungTATheingi Aung
- Kathryn BanfillKBKathryn Banfill
- Mark BaxterMBMark Baxter
Open Access
Abstract
Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.Keywords
Funding Information
- Medical Research Council (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- The Liverpool Experimental Cancer Medicine Centre (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- CRUK Core funding to Manchester Institute (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- CRUK Manchester Centre award (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- CRUK Accelerator Award (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- Wellcome Trust (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- National Institute for Health Research Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- Digital Biodesign and Personalized Healthcare (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
- The Christie Charitable Fund (MR/N025989/1, C18616/A25153, C5757/A27412, C5759/A25254, 29374, 205228/Z/16/Z, NIHR200907, 75-15-2020-926, 1049751)
This publication has 25 references indexed in Scilit:
- Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcomeESMO Open, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyThe Lancet Oncology, 2020
- Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with CancerCancer Discovery, 2020
- Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortNature Cancer, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Determinants of COVID-19 disease severity in patients with cancerNature Medicine, 2020
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyThe Lancet, 2020
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyThe Lancet, 2020